Short Interest in Aclarion, Inc. (NASDAQ:ACON) Rises By 379.3%

Aclarion, Inc. (NASDAQ:ACON) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 148,674 shares, a growth of 379.3% from the December 31st total of 31,021 shares. Based on an average trading volume of 4,557,681 shares, the days-to-cover ratio is currently 0.0 days. Approximately 17.6% of the shares of the company are short sold. Approximately 17.6% of the shares of the company are short sold. Based on an average trading volume of 4,557,681 shares, the days-to-cover ratio is currently 0.0 days.

Analysts Set New Price Targets

ACON has been the subject of several recent research reports. Wall Street Zen raised shares of Aclarion to a “hold” rating in a report on Saturday, December 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Aclarion Price Performance

Shares of NASDAQ:ACON opened at $3.68 on Thursday. The business’s 50 day moving average price is $5.43 and its 200-day moving average price is $6.78. Aclarion has a 1 year low of $3.61 and a 1 year high of $562.68. The firm has a market capitalization of $3.13 million, a price-to-earnings ratio of -0.25 and a beta of 1.44.

Aclarion (NASDAQ:ACON) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.93) EPS for the quarter, missing the consensus estimate of ($2.64) by ($0.29). The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Aclarion had a negative return on equity of 67.53% and a negative net margin of 10,908.50%. On average, sell-side analysts expect that Aclarion will post -263.33 earnings per share for the current year.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.